trauma-care
(7)
The Catheter That Tries to Buy Time Without Stopping It
Prytime built its business around a brutal clock: a bleeding patient needs an operation, but a fully blocked aorta cannot wait forever. Its answer is a balloon catheter that lets surgeons ration the flow.
No Fear Counselling Turned the Hardest Part of Therapy Into Its Business
The Burnaby practice did not invent a new kind of therapy. It made the old kind easier to enter - then used a sprawling therapist network, low-cost training pipeline and two mergers to turn access into the product.
Cresilon Killed Its Big Launch - Then Built a Bleeding-Control Business the Hard Way
A 17-year-old's algae experiment became a syringe of hemostatic gel. The useful business lesson came later, when blackened batches forced Cresilon to cancel a launch and become its own manufacturer.
MAUI Imaging Waited 17 Years for Chips to Catch Up. Now It Wants Ultrasound to See What It Used to Miss.
A father-son garage project spent nearly two decades turning telescope logic into a portable ultrasound system. The first serious proof is in, but the most interesting claims still have to survive larger clinical trials.
Cayuga Biotech
Cayuga Biotech is a clinical-stage biotech developing first-in-class therapeutics that stop life-threatening bleeding by accelerating the body's own clotting cascade. Its lead candidate, CAY001, is a synthetic polyphosphate-silica nanoparticle (polyP-SNP) designed to work where conventional hemostatic agents fall short - non-compressible hemorrhage from trauma, surgery, blood thinners and inherited bleeding disorders. Founded on research from UC Santa Barbara, the company harnesses polyphosphate, a natural cofactor stored in platelets, to normalize thrombin production and speed clot formation without slowing clot breakdown.
Abhishek Ramkumar
Abhishek Ramkumar is the founder and CEO of Abram Scientific, a Menlo Park medtech company building CoagCare, a handheld point-of-care platform that reads the full blood-clotting story from a single drop in under ten minutes. A biomedical engineer with a PhD from Cornell and a B.Tech from IIT Bombay, he spent years at PARC and Blue Highway inventing diagnostic and surgical devices before turning a hard physics problem - measuring blood viscoelasticity and density in a vibration-proof wireless meter - into 17 granted patents and an $11.75M Series A led by Octapharma in 2026. His pitch is simple and life-or-death: get the right transfusion to the right patient at the right time, whether that patient is on an operating table or in a MEDEVAC helicopter.
Abram Scientific
Abram Scientific is a Menlo Park, California medical-device company building CoagCare, a portable point-of-care platform that reads the full blood-coagulation cascade - from clot formation through fibrinolysis - from a single drop of blood in under 10 minutes. By measuring blood viscoelasticity and density on single-use test cards inside a vibration-insensitive handheld meter, CoagCare aims to move coagulation testing out of the central lab and into trauma bays, ambulances, and MEDEVAC helicopters, helping clinicians decide the right transfusion or therapy at the right time.